Neopterin as a prognostic marker in patients with chronic heart failure

Medical Science Monitor

Volumn 16, Issue 5, 2010, Pages

  Wietlicka Kokoszanek, Irmina ^a   Jablecka, Anna ^a   Smolarek, Iwona ^a   Bogdanski, Pawel ^a   Chmara, Ewa ^a   Korzeniowska, Katarzyna ^a   Kazmierczak, Mirosław ^a   Kazmierczak, Ewa ^a   Musialik, Katarzyna ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Heart failure; Neopterin; Prognostic marker

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BISOPROLOL; FUROSEMIDE; METOPROLOL; NEOPTERIN; PERINDOPRIL; RAMIPRIL; SIMVASTATIN; SPIRONOLACTONE; TICLOPIDINE; BIOLOGICAL MARKER;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BLOOD LEVEL; CARDIAC PATIENT; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEALTH STATUS; HEART FAILURE; HUMAN; MALE; QUALITY OF LIFE; RADIOIMMUNOASSAY; TREATMENT DURATION; BLOOD; CHRONIC DISEASE; MIDDLE AGED; PROGNOSIS;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHRONIC DISEASE; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NEOPTERIN; PROGNOSIS;

EID: 77954295391     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Johnsen SH, Mathiesen EB: Carotid plaque compared with intima-media thickness as a predictor of coronary and cerebrovascular disease. Curr Cardiol Rep, 2009; 11(1): 21-27
2. Greig D, Castro P, Gabrielli L et al: Inflammation and endothelial dysfunction in patients with chronic heart failure. Rev Med Chil, 2008; 136(6): 687-93
3. Stumpf C, Lehner C, Yilmaz A et al: Decrease of serum levels of the antiinflammatory cytokine interleukin-10 in patients with advanced chronic heart failure. Clin Sci (Lond), 2003; 105(1): 45-50
4. Djordjevic VB, Stojanovic I, Cosic V et al: Serum neopterin, nitric oxide, inducible nitric oxide synthase and tumor necrosis factor-alpha levels in patients with ischemic heart disease. Clin Chem Lab Med, 2008; 46(8): 1149-55
5. Ariyarajah V: Neopterin: its role in inflammation and coronary heart disease. South Med J, 2008; 101(5): 461-63
6. Adachi T, Naruko T, Itoh A et al: Neopterin is associated with plaque inflammation and destabilisation in human coronary atherosclerotic lesions. Heart, 2007; 93(12): 1537-41
7. Ray KK, Morrow DA, Sabatine MS et al: Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation, 2007; 115(24): 3071-78
8. Pacileo M, Cirillo P, De Rosa S et al: The role of neopterin in cardiovascular disease. Monaldi Arch Chest Dis, 2007; 68(2): 68-73
9. Schroecksnadel K, Walter RB, Weiss G et al: Association between plasma thiols and immune activation marker neopterin in stable coronary heart disease. Clin Chem Lab Med, 2008; 46(5): 648-54
10. Werner ER, Werner-Felmayer G, Fuchs D et al: Tetrahydrobiopterin biosynthetic activities in human macrophages, fibroblasts, THP-1 and T 24 cells. GTP-cyclohydrolase I is stimulated by interferongamma, 6-pyruvoyl tetrahydropterin synthase and sepiapterin reductase are constitutively present. J Biol Chem, 1990; 265: 3189-92
11. Murr C, Widner B, Wirleitner B, Fuchs D: Neopterin as a marker for immune system activation. Curr Drug Metab, 2002; 3(2): 175-187
12. Huber C, Batchelor JR, Fuchs D et al: Immune response-associated production of neopterin - Release from macrophages primarily under control of interferon-gamma. J Exp Med, 184; 160: 310-16
13. Fuchs D, Stahl-Hennig C, Gruber A et al: Neopterin - its clinical use in urinalysis. Kydney Int, 1994; 46: 8-11
14. Mayersbach P, Augustin R, Schennach H et al: Commercial enzymelinked immunosorbent assay for neopterin detection in blood donations compared with RIA and HPC. Clin Chem, 1994; 40: 265-66
15. Fuchs D, Hausen A, Reibnegger G et al: Neopterin as a marker for activated cell-mediated immunity: Application in HIV infection. Immunol Today, 1988: 9; 150-55
16. Chin GK, Adams CL, Carey BS et al: The value of serum neopterin, interferon- gamma levels and interleukin-12B polymorphisms in predicting acute renal allograft rejection. Clin Exp Immunol, 2008; 152(2): 239-44
17. Fuchs D, Weiss G, Reibnegger G, Wachter H: The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious and malignant diseases. Crit Rev Clin Lab Sci, 1992; 29: 304-41
18. Cesur S: Neopterin: a marker used for monitoring infections. Microbiyol Bul, 2005; 39(2): 251-60
19. Kajiya T, Orihara K, Hamasaki S et al: Toll-like receptor 2 expression level on monocytes in patients with viral infections: monitoring infection severity. J Infect, 2008; 57(3): 249-59
20. Gulcan EM, Tirit I, Anil A et al: Serum neopterin levels in children with hepatitis-B-related chronic liver disease and its relationship to disease severity. World J Gastroenterol, 2008; 14(44): 6840-4321.
21. Schroecksnadel K, Walter RB, Weiss G et al: Association between plasma thiols and immune activation marker neopterin in stable coronary heart disease. Clin Chem Lab Med, 2008; 46(5): 648-54
22. Pacileo M, Cirillo P, De Rosa S et al: The role of neopterin in cardiovascular disease. Monaldi Arch Chest Dis, 2007; 68(2): 68-73
23. Yildirim Y, Gunel N, Coskun U et al: Serum neopterin levels in patients with breast cancer. Med Oncol, 2008; 25(4): 403-7
24. Avanzas P, Kaski JC: Neopterin for risk assessment in angina pectoris. Drug News Perspect, 2009; 22(4): 215-19
25. Yndestad A, Damås JK, Øie E et al: Role of inflammation in the progression of heart failure. Curr Cardiol Rep, 2007; 9(3): 236-41
26. Seta Y, Shan K, Bozkurt B et al: Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail, 1996; 2: 243-49
27. Libby P, Ridker PM: Novel inflammatory markers of coronary risk: theory versus practice. Circulation, 1999; 100: 1148-50
28. Agnoletti L, Curello S, Bachetti T et al: Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: role of tumor necrosis factor-alpha. Circulation, 1999; 100: 1983-91
29. Wiedermann CJ, Beimpold H, Herold M et al: Increased levels of serum neopterin and decreased production of neutrophil superoxide anions in chronic heart failure with elevated levels of tumor necrosis factor-alpha. J Am Coll Cardiol, 1993; 22(7): 1897-901
30. Koller-Strametz J, Pacher R, Frey B et al: Circulating tumor necrosis factor- alpha levels in chronic heart failure: relation to its soluble receptor II, interleukin-6, and neurohumoral variables. J Heart Lung Transplant, 1998; 17(4): 356-62
31. Samsonov M, Lopatin J, Tilz GP et al: The activated immune system and the renin-angiotensin-aldosterone system in congestive heart failure. J Intern Med, 1998; 243(2): 93-98
32. Torre-Amione G, Kapadia S, Benedict C et al: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol, 1996; 27: 1201-6
33. Deswal A, Petersen NJ, Feldman AM et al: Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation, 2001; 103: 2055-59
34. Sharma R, Coats AJ, Anker SD: The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endtehelin-1. Int J Cardiol, 2000; 72(2): 175-86
35. Torre-Amione G: Immune activation in chronic heart failure. Am J Cardiol, 2005; 95: 3-8
36. Rivera M, Taléns-Visconti R, Jordán A et al: Myocardial remodeling and immunologic activation in patients with heart failure. Rev Esp Cardiol, 2006; 59: 911-18
37. Fuchs D, Samsonov M, Tilz GP et al: Stimulated cellular immune system in patients with congestive heart failure. Eur J Clin Chem Clin Biochem, 1993; 31(3): 111-14
38. Aukrust P, Ueland T, Müller F et al: Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation, 1998; 97(12): 1136-43
39. Nessler J, Nessler B, Kitliński M et al: Concentration of BNP, endothelin 1, pro-inflammatory cytokines (TNF-a, IL-6) and exercise capacity in patients with heart failure treated with carvedilol. Kardiol Pol, 2008; 66: 144-51
40. Svoboda P, Ko SH, Cho B et al: Neopterin, a marker of immune response, and 8-hydroxy-2'-deoxyguanosine, a marker of oxidative stress, correlate at high age as determined by automated simultaneous highperformance liquid chromatography analysis of human urine. Anal Biochem, 2008; 383(2): 236-42
41. Grammer TB, Fuchs D, Boehm BO et al: Neopterin as a predictor of total and cardiovascular mortality in individuals undergoing angiography in the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem, 2009; 55(6): 1135-46
42. Mulder DJ, van Haelst PL, Wobbes MH et al: The effect of aggressive versus conventional lipid-lowering therapy on markers of inflammatory and oxidative stress. Cardiovasc Drugs Ther, 2007; 21(2): 91-97